Cushing's disease market is expected to reach USD 1.1 billion by 2034

Cushing's disease is a rare endocrine disorder caused by excessive adrenocorticotropic hormone (ACTH) secretion, usually due to a pituitary adenoma. This leads to hypercortisolism (excess cortisol), resulting in symptoms such as weight gain, muscle weakness, diabetes, hypertension, osteoporosis, and psychiatric disturbances.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71973

If untreated, Cushing's disease significantly increases morbidity and mortality. Current treatment options include pituitary surgery, medical therapies targeting cortisol production or action, and radiotherapy.

The global market is expanding due to increasing diagnosis rates, orphan drug incentives, improved pituitary surgery techniques, and development of novel ACTH/cortisol-targeting therapies.

Market Overview
• Market Size (2024): USD 560 million
• Forecast (2034): USD 1.1 billion
• CAGR (2025-2034): 7.0%

Growth is supported by greater disease awareness, orphan drug approvals, and precision medicine in endocrinology.

Key Highlights:
• Cushing's disease affects ~40 people per million, classifying it as an orphan disease.
• First-line therapy remains transsphenoidal pituitary surgery.
• FDA-approved drugs include pasireotide (Signifor), mifepristone (Korlym), osilodrostat (Isturisa), and metyrapone.
• Pipeline biologics and gene therapies under investigation.

Segmentation Analysis
By Product Type:
• Pharmacological Therapies
o Pituitary-Targeted Drugs (pasireotide)
o Adrenal Steroidogenesis Inhibitors (conazole, metyrapone, mitotane, osilodrostat)
o Glucocorticoid Receptor Antagonists (mifepristone)
o Pipeline Agents (relacorilant, levoconazole, gene therapy approaches)
• Surgical Interventions
o Transsphenoidal Pituitary Surgery (standard of care)
o Endoscopic & Minimally Invasive Pituitary Surgery
• Radiotherapy
o Conventional Radiotherapy
o Stereotactic Radiosurgery (Gamma Knife, CyberKnife)
• Diagnostics
o 24-Hour Urinary Free Cortisol Tests
o Late-Night Salivary Cortisol
o Low-Dose Dexamethasone Suppression Tests
o MRI Imaging of Pituitary Adenomas

By Platform:
• Small Molecules (steroidogenesis inhibitors, receptor antagonists)
• Biologics (pituitary-targeting biologics, gene therapies - pipeline)
• Devices (surgical systems, imaging platforms)

By Technology:
• Long-Acting Injectable Formulations
• Next-Gen Steroidogenesis Inhibitors
• AI-Enhanced MRI for Pituitary Tumor Detection
• Gene Therapy Platforms (experimental)

By End Use:
• Hospitals & Endocrinology Clinics
• Specialty Rare Disease Centers
• Diagnostic Laboratories
• Research Institutes

By Application:
• Pituitary Adenoma-Associated Cushing's Disease
• Refractory/Relapsed Cushing's Disease
• Clinical Research

Segmentation Summary:
Medical therapies dominate today's market, but pituitary surgery remains first-line, and pipeline biologics and gene therapies are the fastest-growing areas.

Explore Full Report here: https://exactitudeconsultancy.com/reports/71973/cushing-s-disease-market

Regional Analysis
North America
• ~43% share in 2024.
• Strong adoption of FDA-approved therapies and advanced pituitary surgery.
• Orphan drug designations driving R&D.
Europe
• ~31% share.
• EMA approvals of osilodrostat and pasireotide boosting adoption.
• Germany, UK, and France leading in specialized rare disease care.
Asia-Pacific
• Fastest-growing region with CAGR of ~8.0%.
• Rising diagnosis in Japan, China, and India.
• Expanding access to endocrinology centers and novel therapies.
Middle East & Africa
• Smaller market share, but improving rare disease recognition.
• Limited specialized endocrinology infrastructure.
Latin America
• Brazil and Mexico leading adoption of generics and advanced diagnostics.
• Expanding rare disease healthcare frameworks.
Regional Summary:
North America and Europe dominate due to strong orphan drug pipelines, while Asia-Pacific grows fastest due to expanding healthcare infrastructure and awareness.

Market Dynamics
Key Growth Drivers:
• Increasing diagnosis and awareness of Cushing's disease.
• Expanding orphan drug approvals and R&D incentives.
• Advances in pituitary surgery and imaging.
• Development of new steroidogenesis inhibitors and receptor antagonists.

Key Challenges:
• Delayed diagnosis due to non-specific symptoms.
• High cost of biologics and orphan drugs.
• Small patient pool limiting large-scale trials.
• Recurrence rates after surgery remain significant.

Latest Trends:
• FDA and EMA approvals of osilodrostat and relacorilant.
• AI-assisted MRI for early pituitary adenoma detection.
• Exploration of gene therapy and novel biologics.
• Patient advocacy groups driving rare disease awareness.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71973

Competitor Analysis
Major Players in the Market:
• Novartis AG (Signifor - pasireotide)
• Recordati Rare Diseases (Isturisa - osilodrostat)
• Corcept Therapeutics (Korlym - mifepristone; relacorilant pipeline)
• HRA Pharma (metyrapone)
• Pfizer Inc.
• Ipsen (endocrinology portfolio)
• Sun Pharmaceutical Industries Ltd.
• GE Healthcare (MRI imaging for pituitary adenomas)
• Siemens Healthineers (neuroimaging solutions)
• Amryt Pharma plc (rare endocrine pipeline)

Competitive Summary:
Novartis, Recordati, and Corcept lead in approved therapies. HRA Pharma and Ipsen expand adrenal steroidogenesis inhibitor portfolios. GE and Siemens provide advanced imaging solutions. Emerging biotechs focus on gene therapy and novel pituitary-targeted drugs.

Conclusion
The Cushing's Disease Market, valued at USD 560 million in 2024, is projected to reach USD 1.1 billion by 2034, growing at a CAGR of 7.0%. Rising rare disease awareness, improved diagnosis, and pipeline therapies will continue to drive market expansion.

Key Takeaways:
• Surgery remains first-line, but medical therapies dominate ongoing management.
• North America and Europe lead, while Asia-Pacific grows fastest.
• Osilodrostat, pasireotide, and relacorilant reshaping treatment standards.
• AI diagnostics and gene therapy represent future breakthroughs.

The next decade will transform Cushing's disease care from delayed recognition and limited drugs to precision endocrinology with biologics, AI, and gene therapy, creating opportunities for pharma, biotech, and medtech innovators.

This report is also available in the following languages : Japanese (クッシング病 - 市場), Korean (쿠싱병 - 시장), Chinese (库欣病--市场), French (Maladie de Cushing - Marché), German (Cushing-Syndrom - Markt), and Italian (Malattia di Cushing - Mercato), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71973/cushing-s-disease-market#request-a-sample

Our More Reports:
BRIC Embolization Particles Market
https://exactitudeconsultancy.com/reports/72341/bric-embolization-particles-market

EU5 Embolization Particles Market
https://exactitudeconsultancy.com/reports/72340/eu5-embolization-particles-market

North America Embolization Particles Market
https://exactitudeconsultancy.com/reports/72339/north-america-embolization-particles-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.